- Home
- RRR vs AKRO Comparison
RRR vs AKRO Comparison
Compare RRR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | AKRO |
|---|---|---|
| Founded | 1976 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.5B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RRR | AKRO |
|---|---|---|
| Price | $56.19 | $54.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 10 |
| Target Price | $61.40 | ★ $73.56 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 10-28-2025 | 11-07-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 15.51 | N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $1,995,401,000.00 | N/A |
| Revenue This Year | $4.13 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $17.92 | ★ N/A |
| Revenue Growth | ★ 4.69 | N/A |
| 52 Week Low | $35.09 | $21.34 |
| 52 Week High | $63.60 | $58.40 |
Technical Indicators
Market Signals| Indicator | RRR | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 66.54 |
| Support Level | $58.02 | $54.22 |
| Resistance Level | $59.93 | $54.70 |
| Average True Range (ATR) | 1.76 | 0.14 |
| MACD | 0.10 | -0.11 |
| Stochastic Oscillator | 46.70 | 64.18 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.